JNCE - Earnings call transcript Q4 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen and welcome to the Jounce Therapeutics Fourth Quarter and Full Year 2018 Earnings Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time.

As a reminder, this conference call is being recorded at the company’s request. I will now turn the call over to your host, Komal Joshi with Jounce Therapeutics. ahead. go Please

Komal Joshi

outlines Good the fourth operator. conference welcome the our release www.jouncetx.com. release, to This to at we Thank today. website and discuss and morning Media full Therapeutics The which press a quarter we available results topics year Jounce that morning, plan in you, is issued and the Investors XXXX call. of financial section

financial progress will and CEO our review milestones XXXX Speaking clinical on update lastly, discuss President, Kim will activities, and Rich by our Murray, will on our development pipeline Beth will Drapkin, followed our today’s XXXX, review and who Dr. Trehu, key XXXX guidance. Dr. for be financial the CMO, full provide our preclinical CFO, call our and who an year

then for open call the will your We questions.

I discussion today’s provisions Private plans statements results begin, filings. Safe those of everyone we may in of risk SEC Securities future will prospects discussed important the include would statements for that forward-looking like remind expectations, factors, differ XXXX. a about various constitute the forward-looking our purposes as factors Actual and to of by that Before the under statements these from including indicated our materially the Reform Act Litigation Harbor result

statements as our representing views In as of any views relied upon date. should forward-looking our addition, today, any and only as represent be March X, not XXXX subsequent of

over now forward-looking elect change. call even statements views specifically in these if some to the so will Rich. to any turn that, future, may do disclaim update I With While to we we at the obligation point our

Rich Murray

ICOS our year clinical centered everyone. We XXXX Thanks, milestones, several advanced or JTX-XXXX, candidate, Jounce. Komal data for the important and development. which from of vopratelimab around product mechanism two the rationale next our agonist. formally accomplished strong scientific for of vopra and and into was several an We key insights morning, important trial which action most good at demonstrated ASCO stage reported ICONIC vopra’s readouts SITC, of

the which important three improved represent platform, analyze ICOS patients data to As we overall meeting biomarker at clinical announced, Using include Translational we an posters biomarker. and survival Science the our AACR new in upcoming we annual survival on progression-free develop both recently with scientifically validation and began of demonstrating XXXX designs to biomarker our will dose June enrollment We strategy escalation studies. trial announce thus and clinical cohorts ipilimumab in potential have biomarkers. based safety are we new with rationale predictive today of supporting Phase pleased with established new safety that combination combination pembrolizumab combination X with and in and we driven

as immunotherapies. target, We about JTX-XXXX therapies so example we poster pathways and providing annual known macrophage our checkpoint. broader JTX-XXXX XXXX look meeting more few a to also excited far. first-in-class of AACR in studies. in our the advance of types discover the associated JTX-XXXX cell as data a tumor an involve to IND-enabling which targets We also represents advancement In forward LILRBX macrophage immune information multiple we see candidate, vision announced pipeline of the into JTX-XXXX continue by to our we macrophage are have analogous first that new weeks. ILTX, a we to seen at a and

cohort advanced completed in and inhibitor also XXXX. in fourth clinical PD-X enrollment We JTX-XXXX, trials of our X Phase quarter at our the first the

and three role highlight mainstay ever each. direct patients will scientific On and provide to we key to note, highly reverse with playing this future in PD-X translational let the elements of come an benefit that believe will of combination than me at important hope our JTX-XXXX, like long-lasting stated, immunotherapy. therapy be of of previously in we be product treatment and you combination And likely that give candidates. inhibitors the later We to As and on will approach. checkpoint are Beth we a immunooncology believe transform examples more success cancer from approach believe what cancer

this to and Early in used biomarkers. our foremost, patients. process will potential the development identify multiple translational science evaluate the we right First predictive platform

of More are with clinical use any of available and importantly unique platform we our from trial, the association biomarker to patients. the once non-responding versus responding data clinical then characteristics the identify in mechanism action

focus a it whether they to scientific is move rationale necessary strong irrespective centric PDX on Second, the our included inhibitor. we with inhibitor beyond PDX believe approach, of combinations

do Third, it’s T-cells. critical not to address need in that have tumors the unmet

by may either tumors these T-cell to dominated immunotherapies. do Some not be or macrophages cold which immunosuppressive of directed respond well

are diverse regulatory types cells a and macrophages including targeting building T immune targets. cell immunosuppressive pipeline stromal We multiple

address Our an Celgene under pipeline acquired Myers and January three these partner of approach Squibb. In our agreement important all may elements. Bristol Celgene by which announced be

BMS BMS. As for there planned, in overlap of $XX.X our is XXXX, as continues for and upfront and understand activities prior to we lead clinical We we Celgene. see conducts any Jounce. leads Celgene great any opt-in. funds outcome acquisition in a having partner pipeline, positive forward reminder, closes regardless equity and that us as assuming but programs $XXX look an investment we and consequences from working Celgene million BMS’ be with a a to partner received payment million have Jounce non-refundable to all of

now rights strong like Beth will partner either science un-option to program more the we call a have XXX% more our to in to in our opportunity it turn worldwide advance the will and retain the discuss We own new and the IL I the field in for Beth? or pipeline potentially any with on over would detail. of have to BMS partner.

Beth Trehu

for from clinical and as and everyone. is exciting progress. translate important Jounce into This analyses good morning Rich an time Thanks preclinical learnings clinical trails we the our

population plans of like the T trial. in with In XXXX Our Phase and a has into reverse a ICOS future am biomarker start and progress characteristics pharmacodynamic cells. associated reductions rationale going our ICONIC specifically an the has trial the work I next T our with critical and clinical X, ICONIC pharmacodynamic ICOS effector us and I would studies This CDX blood have provide the CDX of with in translational pleased scientific on in vopra an for set trails strong X activated of provided been XXXX. tumor to the update informing which vopra. our for interpretation from were data Phase peripheral high biomarker cells of emergence of X to

emergence who be The levels T emergence development vopra. ICONIC demonstrated the emergence separate cells the for We relationship two In we between express characteristics present present due and of of that about of T providing more details showing activates these cells ICOS AACR clinical CDX at have CDX requirement paths. they not high a and weeks clinical on have vopra cells has that vopra cells. if activated will one overall these for activity providing progression CDX vopra ICOS. few and have is survival analyses, shown these In patients to and PDX T we inhibitors. of and cells high these in to of improved only two effector cells led data the One posters free benefit to

ongoing shown high blood, the new been X not, strong has development cells to is inhibitors combination important translational this do vopra of peripheral ipilimumab PDX of cancer ipilimumab. reverse Based of we clinical Phase work, and while be induce on in non-small inhibition of with scientific will this studies combination in year cell there with bladder cancer. in both lung initiating CTLA since in vopra the the First, population ICOS rationale

who second are The selection on new path that is likely the more to benefit. biomarkers based predictive enrich patient patients for may

did cells platform more applying ICOS identified whom than trial, trial on non-responders samples comprehensive the to analysis high the a responders with with data is have an emergence on in emphasis our analysis biomarkers understanding of candidate differences and reverse T strategy subset blood inform cells CDX between ICONIC We emerge. patient from believe relying patients not preclinical characteristics baseline of to and selection the that treated clinical relevant predictive baseline and data. our of a of of all We translational to these tumor

mentioned vopra the therapies pharmacodynamic macrophages. would At that survival. are to XXXX This to in of I cells Jounce, vopra. role studies types X validates next alone. We data program, immunosuppressive T types believe in in which turn may with tumor for preliminary first-in-class data progression-free biomarker now us JTX-XXXX, of ICOS like and we improved CDX efficacy the immune our Phase shows at with cell have not innovative tumor-associated emergence allow plan to being targets develop ICONIC of initiate therapies that next cell responsive ICOS clinical directing As finding different targeting the to directed expected XXXX. to strategy clinical new further presented stage overall patients AACR for this the the high that T development

an analogous tumors. goal interaction the may likely to to this hope to to to to multiple and an binds target the immune tumor macrophage PDX is or or macrophages its is on phenotype we inhibiting checkpoints immunostimulatory micro breaks by an believe be immune release LILRBX’s ligands, require phenotype. anti-tumor binding an the JTX-XXXX the Similar By which evasion convert immunosuppressive resulting checkpoint. also a such MX from a ligands, When immunosuppressive to targeting strategy is state of cell LILRBX, in Our types. this its employed We created. is to immunosuppressive the immunosuppressive other environment of reprogramming LILRBX MX environment of immune-activating CTLAX, to ligands

evaluation few in micro we will associated JTX-XXXX that reprogramming preclinical the a just product its the poster of macrophages at will and within in role weeks a candidate environment. describe this exciting mentioned on AACR, present As tumor also tumor

you Phase forward progress. JTX-XXXX IND on continued file We and to the to updating of expect the later study this year X our initiate look and

Finally, immunetherapies, conveyed on this recommended In to later development development. to continued early today’s clinical which dose our Jounce we applying in and way to inhibitor unique on of which for clinical I first-in-class JTX-XXXX remain pharmacodynamic of touch to preclinical from of hope that clinical reverse our Phase biomarkers PD-X through predictive the would the incorporation to identify potential update, track we year. translational approaches have Translational Science I X and like the development platform data inform analysis

Now, discussion year financial XXXX review results to I full Kim? the of XXXX guidance. a call for to and our our of like Kim would turn over

Kim Drapkin

everyone. morning good and Beth Thanks,

cash, increased our with million million release, federal of $XXX.X As XXXX to for cash in line press cash in the to $XXX by ended equivalents we we reported the to this compared receipt and during totaling investments guidance The is XXXX. and was tax This $XXX.X state in $XXX income XXXX million. decrease million morning’s with refunds. due operating costs of incurred financial offset year

of recognition Turning to that payment $XX.X a year collaboration XXXX. XXXX compared July the $XX.X million currently receipt upfront full the P&L, the Celgene Recall for was XXXX. in for our collaboration non-cash, revenue to revenue million reflects

XXXX, decreased million million of increased $X were The in of external for incurred During expenses $X.X of by XXXX R&D decreased clinical to administrative research $XX.X million increased was and for $X.X to General lab in the increase and The in million costs is diluted and net expenses $X.XX and compensation compared XXXX. $XX.X basic basic to and and January. in full development for per XXXX $XX.X $X We million $XX.X expenses costs million employee external an driven as expenses decrease million or $X.XX. regulatory we collaboration $XX.X a due million costs. increased year in million expenses. XXXX increase $XX.X guidance by for loss revenue we offset purchases. costs compared for XXXX. a of XXXX of employee loss of primarily G&A increase and consumables compared a would provided in and share diluted net million non-cash to Net the loss or compensation of result per the financial operating net XXXX increase was share of in This loss R&D a reiterate was

million continued expect the expenditures on and expenses burn to $XX operating to cash full be We approximately year XXXX for to capital $XX million.

to $XX We million. also collaboration non-cash continued expect revenues million $XX of approximately to

the and to next fund our our our plans will and cash sufficient allows call us and immunotherapy I months. back expect plus the existing execute investments us Based against operating drive to capital operating turn to on expenditure our With the expenses cash, over balance be that, requirements strong at we plans, current least goals. Rich. enable XX sheet strategic efficiently innovative our equivalents will to flexibility for Our pipeline

Rich Murray

Thanks Kim.

will XXXX the advancing I opening milestones. our your call be like that important Before we as questions, incremental and would to report data reiterate execute our on focused on to pipeline anticipated

and Importantly, we capitalized programs our are additional forward. new drive development well to candidates bring

who professionals that culture dedicated and strong team the developing durable built with benefits have cancer of therapies focused to on remain innovative patients. talented and We the discovering bring

JTX-XXXX, discovery up candidates of this lot the Phase vopra, reiterate, data safety, of X enabling As tolerability into dose OS have X development to next our of and call we on ICONIC advancing like PFS new file three report to lead form initiate To a and Operator? at would With work into we JTX-XXXX questions. the to plan and the X our studies we year the that, continued IND IND for updated your of AACR, establish for initiate such recommended Phase Phase candidate and coming now trial development vopra open our pipeline. studies.

Operator

Kasimov [Operator from you. comes And Instructions] our of JPMorgan. Cory Thank first question

open. now is line Your

Unidentified Analyst

Hi, Cory. this is Carmen on for my taking question. for Thanks

trial, at first if that missed you make Phase what’s ongoing X? data when apologize you to this, would I you the take when the something I decision the dose present would look XXXX a able we might is from for be get to the to So

Beth Trehu

This is sure to Phase disclose that now. Beth, X to into this dose just given will Phase present Phase point may X possible. as at we as haven’t we escalation, would so data, wait that data, X the and when Hi. a disclosed am like not I right Phase X it’s And we but decide move quickly we

Unidentified Analyst

then that Okay. of Ipi paths mentioned XXXX in to be you agnostic path likely clarify kind would provide more then just a kind how that was combination And the and tumor more patients and of to second bladder about approach if are you potential for two you. identifying forward benefit, lung thinking or Thank just wanted one you could with I detail?

Rich Murray

certainly Sure. a and as and it and could will science find to work a bladder. combination indications across KOLs We the predicted to is with immune In opportunities as types think the cell looking landing that the through that, with on to technology in Rich internal We of non-small with we of the there is we course agnostic. offer have got comment that lot indications right have biomarker I are tumor this but speaking. got the for Yes. and Ipi the of on – manner space, our potential done committee be cuts those patience. system indications we

that’s So, had, we more on but direction details good would that later.

Unidentified Analyst

Thank you. great. Okay,

Operator

Cowen. question from next Boris Thank you. And Peaker comes our of

now is line Your open.

Boris Peaker

associated upon of activity, as biomarker is morning. could vopra curious observation Great. something I question am you a My the of the first Good of is that that drug just noted be peripheral cell as treatment? shortly efficacy T starting with used to monitor the

Beth Trehu

great Yes, that’s a Boris. question,

multiple I think it has potential uses.

could So it’s can emerge, monitor looking combining see we other for yes, we can we we to at allows ipi, their us a drugs but if other we agents of a but ipi, good give patients that potentially treatment, degree after the unsteady combine to it investigators may potential and importantly, as good a vopra, are be strategy, particularly way sense that tool help the certainly whether those start vopra in can us predictive identify cells, on a can can looking in whom similar certainly also it such cells real-time then us the not. it or keep patients it with biomarkers which to these at monitor look gives that after something to with with potential

Boris Peaker

done is of clear ICOS lot derived biomarker, And on evolving what second threshold still it. a have high confident you am question just curious on of the feel the is that you definition that kind you target? biomarker, moving obviously work I of ICOS do a or Got of have

Rich Murray

that from we associated take data emerges. the one we see seen, vopra, have see emergence, that we with do Yes, population Yes, Boris. pattern so of do clear robust that a it’s will I a

of set we So Beth run kind that how assay have criteria is all around purposes for in validated went and this have through. the conditions that

be in add convenience seen one when is at of of is and that we and there continued cells, patients SITC progress, – So, the then maintenance of feel I positive. cell cells correlation those population, confident disease. the in of is then as in more at we positive it and maybe association it with but and kind is to population kind the the the have upcoming disease in of we of mean, of AACR reported achieved cells progressive in of relatively this comfortable the positive kind well, there I of seen the kind so benefit of note will the being of at kind is and the a helps not there have we also that really that, then biomarker type losing kind have see association blood long lose frame population type will stable we that obvious having patients – responses When feel that the that patients the durable state. tumor

Boris Peaker

with And perspective it. expect we of as properties that system, kind about it just would just cancer do decline of and kind to the indicative mentioned you health progression what know this correlative disease the kind biomarker lastly biomarker? immune how you of is just cells, possible on immune defeats losing just overall it the and biomarker, that Got the versus the so it’s of that of of

Beth Trehu

Sure.

profiling a SITC, those did at inhibitors So PDLX as including in study or of not responses. we patients had patients peripheral X it did and singed their who were we where PDX treatment with who either we intensive XX of inhibitor, looked a patients on we PDX have presented blood and separate receiving at did any confirmed

on seen and we the with that’s cell it. the not some high have which active as immune done, cells vopra. it CDX be at something think have particularly health, of really we that’s in see And we have patients, may patients, we of seen although in cells of were consistent PDX than but directly did ICOS to So just more biology, maybe but the ways or would those on marker think appear the we have in some the a least have inhibitors emerge also we with does being associated treatment, out, work something those responding cells patients on do if it’s biomarker, at beginning it it all a we find CDX that you heard using predictive primed to

Boris Peaker

very my taking Thanks much questions. Great. for

Beth Trehu

You are welcome.

Operator

next Fargo. James our question from Birchenough, And comes Wells you. Thank

now is line Your open.

James Birchenough

that Yes, with all translational the you Congrats on how in study of inducing just with ipi hi first looked that guys. at I it induce the that long ICOS terms guess to insights reverse just for of interest the high progress you response, the take question safety and have have high work. state? time the in CDX vopra the is ipi course you have done ICOS if into does

Beth Trehu

that literature of safety who Sure. kind Yes, cycles induction the its others ipi by ipi definitely timing. on are emergence the have the or by Jeff or and dose X during vopra the the first of shown the Sharma, data generally its study, we ipi. in come Weber, X of looking publications kinetics therapy. from from Pam And appears studies, with of it at escalation the Most

James Birchenough

terms expected seem combination long ipi, results one some dose ipi, the benefit, you long of combination And back the get enough, can I with you is from you if in has in vopra just that to could get drugs iconic enough gone things of in the saw results? how struck to that two dose us with the that

Beth Trehu

Yes.

and safety data next not study. forward the tolerable at from and as but are point, sharing Rich to the we we phase the So, with dose this supports the it really profile vopra of moving ipi mentioned, have do escalation

we enough something benefit. add as mentioned helpful whether those be treatment monitoring, anything? to we earlier to give and on long So, will And but think maintain biomarker patients that’s in obviously investigators’ data to you I are being emerging helping able will the be cells want to Rich on feedback other

Rich Murray

in relapsed Jim, to for patient move I refractory on track kind of is kick able that to also patient to on population, immune as there that you these could in. being if lines be will populations Yes. of as another to healthier in opposed mechanisms therapy being enough will a the long therapy we stay angle population two think think we

James Birchenough

you of to CDX guess have then the metric response part at just the trying or cells, that data at looking finally you cells And for just as at infiltrating those in tumor? at we look should question shrinkages ICOS look data as we not disease just the patients but whether tie AACR, also the necessarily and peripheral just an second if the I looked PFS response, OS will resist well? tumor biology are have altogether, high is get And important the stable CDX tumor

Rich Murray

the Yes, question. one then of I on can Beth will the last comment take part that first and

activated kind looking with but would vopra location published So, we clinical kind be to you have more of will I second characterization of them yes, that, will cells on tracking and periphery to that would that characteristics say JTX-XXXX. refer have more poster, various tracking well two of for the AACR one tumor cycling have but much the to they can’t we would the got is abstract all comes mechanistic as a pickup posters different find on one the continue before And vopra, these expect at too in the be the ways. addition, that kind cell. as out, cells them then means OS T also will PFS our of data, at the we which Effector in a of we

Beth Trehu

core we of But are there is of the also responses really baseline than the we durability that so be characteristics feel more be now, I we the yes, biomarker. and and so we these just to exciting will durability reviewed updated data seeing Yes. think compelling the with are is particularly had most And on the the have will what responses, into that the that the and we that in patients the obviously question you put and in to them then of the previously context. centrally you reported. correlation of data is kind And help really have patients, what will that with then respect digging your is see about PFS data why getting so there OS but characteristics of the immunotherapy

Rich Murray

Yes, yes, that earlier about leads tumor potential. question agnostic into the the of kind

James Birchenough

for taking questions. Thanks Great. the

Rich Murray

Sure.

Beth Trehu

You��re welcome.

Operator

Thank our of question Mike W. Baird. comes you. And next Ulz from Robert

Your line is open. now

Mike Ulz

guys, you the taking Hey current can talk just based your about on And dose for the X of question. Phase press current the some the you’re if sounds you Maybe terms thanks X release for escalation can maybe considering status different it JTX-XXXX dose thinking of ongoing go-forward combinations? schedule the the for there? just Phase like in maybe

Beth Trehu

Yes.

you we’ll escalation providing have take not some dose makes studies yes, the in that’s schedule to on June forward based do started safe the details details, we but determined and the dosing be in the So, changes a we’re that feel in biology we dose lot well future. in sense more know new providing tolerated. and as the and yes, the of them And about

Rich Murray

of that and expansion the priming kinetics of looking and these optimally could how create with that we we in from the that to dose think – ipi to we is how of for Yes, threshold the of lower vopra. then for kind come are back of kind cells populations part Mike

Mike Ulz

Thanks. helpful. That’s it. Got

Operator

next H.C. our of Chattopadhyay comes Wainwright. question Debjit from And you. Thank

now Your line open. is

Debjit Chattopadhyay

Hey, good morning.

that for June particular in cell XXXX initiated or phenotype, was T – clarify, for of requirement phenotype, something in implemented this the to ipi getting future is in this So, implemented that’s just the all combo studies?

Beth Trehu

we sure safely. And the at to be together ICOS but emergence the safety a all included that ahead, anticipate those patients patients will we at cells serving forward, select but be purely be T going we no, to in one won’t studies, escalation So, because go those the predictive of in our hi not ipi biomarker-driven it particular will generating CDX then at drugs separate looking biomarker will give yes. necessarily of looking to that we baseline respond be dose that And potential a selecting sorry, of studies, be think looking could do vopra, are make ipi study. that that two better cells will in function was well, the the can studies –

Debjit Chattopadhyay

Yes.

make up would So, be would of patients terms think show these these just one of is that the have ability therapy in this difference the your traditional the – are likely tumors, just that your lines to terms specific that would have biomarker on are types up phenotype, expression of there in in prior this? this that you tumor and in or this ipi-sensitive following of of also And predictive to does other terms had, that actually of at ipi’s induce current percent a what patients in – looking biomarker? dataset,

Beth Trehu

that disclose ICOS about that. hi details a at is from more we’re biomarker, we’re on We shown patients patients and people information the who lot emergence these about type cells we’ve in in group, XX all T did to a actually prepared CDX in it data of emergence in of XX XX reductions not had of what of and who tumor predictive terms this and this didn’t, not – who in had So, had the present and the the of of subset was it. patients cell looked study people

tumor Sharma It’s the been it’s small been cancer, obviously shown since cells, different other types. one of of induction Pam which shown tumor important of going shown series, in also in bladder in we’re it and into, terms is in that’s the tumors in in demonstrated very melanoma, types. these has been So, several it’s

particularly there of think I is think answer did don’t this all And – more So, tumor-specific questions. to a phenomenon. we it. I Is your

Debjit Chattopadhyay

the of terms in one therapy lines – of of Yes, there impact prior the was

Beth Trehu

that lines thank tumor that patients these Yes, yes. cells but therapy, data AACR. actually you. also the our disease prior characteristics in actually very had of lung heavily on their emergence is based saw reductions cell of poster non-small to in really pretreated, stable we from some inhibitors emergence durable cells. the what’s and patients yes, of were cancer of our of Oh, And and Well, and had therapy PDX be these interesting who we ICONIC the more and relationship to about will specifics study providing patients types in failed

will from So, by more you will that. think a the you poster, lot see come information hope and I get

Debjit Chattopadhyay

Yes.

Just in expanding patients? be primarily this on on and PDX would [Technical low Difficulty] cisiplatin again obviously into, eligible

Beth Trehu

No, who have patients, we into PDX or are a progressed inhibitor. on going patients received after PDX so experience and

Debjit Chattopadhyay

Great.

Beth Trehu

am sorry know, that’s a go As really I – you ahead.

Debjit Chattopadhyay

ahead. Go I just one had more.

Beth Trehu

Yes.

growing the know therapy, you as care. whom inhibitors lines one of experienced is move into as is PDX patient the a need of not a really earlier unmet for now that’s standard So there population PDX

And large who steady combination be immunotherapy remain the on treating provides to point into unmet us it’s treating populations, Rich made will – to we the to an the think patients we need, these by with. longer so less reap and able a for but patient also that are pretreated at of heavily opportunity moving hopefully it are the before little address benefits healthier them we

Rich Murray

you PDX. cell from population that’s and if ICOS the of necessarily mechanism mechanism CTLAX in ipi benefit patients and the more non-small Yes. we that other that Maybe looking will cancer, cancer, fact lung point cell not detail one again just who at so depended non-small at show on a in cell as the experienced lung well of induction AACR, as as to the PDX related did on see and

Debjit Chattopadhyay

Great. last with yours and gaining anything for obviously regarding GSK you which some what in And are as the versus terms well? differentiation stuff, strategy investigators any the and to program have of seen one they might one GSK traction your from hearing seems me,

Beth Trehu

only it. what Yes, their know we much lot they that to they to-date so And actually what because big information. but kind clinically, get putting program to a it’s of of leads terms investment a that haven’t that that seen we is us we excited and in difference to are they hard said are GSK try seeing really publicly don’t and haven’t information. there very know has are that tell, We ICOS anything into think of presented about

Rich Murray

year from this GSK information I we at… Yes, are later think anticipating

Beth Trehu

year. the of half Second

Rich Murray

year. the of half Second

Debjit Chattopadhyay

so much. you Thank

Beth Trehu

you. Thank

Operator

question Raymond Thank our you. And Steven James. Instructions] [Operator comes from Seedhouse next of

now is open. line Your

Steven Seedhouse

you. Good morning. Thank

PFS the just what upcoming high is to presentation in in to improved patients? of patients, high controls relation historical OS and or ICOS that will you the can AACR piece non-ICOS show mentioned You the clarify

Beth Trehu

high ICOS the ICOS low versus looking it’s patients. the Yes, at

Steven Seedhouse

Okay.

Beth Trehu

overall the at steady looking population. also And

Steven Seedhouse

you you. where was you to patient looked trying the of the ICOS biomarker, have T this treated itself samples in patients, high thank And treatment? archived understand cell cell, have from the CTLAX that actual T ever Okay, population biology just ICONIC or the before identified in present at a

Beth Trehu

not aware am the to published treatment. data the prior the data any there, blood of these cells ability to From suggesting in detect peripheral I

Steven Seedhouse

Okay.

Rich Murray

Steve, maybe I could comment on that.

that that thing a one kind are a for necessarily sequence of of of or population tumor. if is patient combination variety or kind expanded why way that get how in at that the the to expanded is new kind think there the be person you the of particularly an or populations. I ipi of cells. been thinking be we include could you specific was priming an But could reasons is biology we think T hopefully wouldn’t the lowering influenza expand and quickly next thresholds could do population which here the from that that hopefully cells about least the ipi tumor there would vaccine It’s of events it is key have unusual

way kind looking of at that’s are So biology. the the we

been We something that’s will continue there haven’t reports nor seen but and of had to at. published pre-existing, we obviously look

Steven Seedhouse

CTLAX the of were or suggest on responders persist biomarker, it a again looked complete biology so lastly response? the the biomarker treated does durable the in with just if persist might complete at you would a And patient any that and Okay. patients

Beth Trehu

Yes.

you was at, what induction saying improved cells not gets CTLAX the beginning you But interested data terms at this am have that of we that mean in showed sure patients that Rich in CDX persistence you keep say to that know importantly of with in I that in can us so stop very given maintain and whereas our that cells, lose patients very hands start would be the to one looked vopra Pam I ICOS giving of that when JTX-XXXX things it’s had literature of but showed the Sharma cells. the So stable after the with those definitely far safe being high ICOS got what And survival. that you correlated really was that point of to ipi something and and those do which earlier population cells. at disease have can’t you we some

Steven Seedhouse

Okay. Thanks the questions. for clarifying and thanks for

Beth Trehu

Thank you.

Operator

concludes and in day. Everyone may conclude and that thank gentlemen, participating the disconnect. for all session for today’s program And have does This conference. today. you a great you. Thank Ladies our you question-and-answer

Jounce Therapeutics (JNCE) 6 Mar 192018 Q4 Earnings call transcript